October 27th 2023
An overview of safe treatment options for migraine attacks that may occur during pregnancy for primary care clinicians, here.
September 25th 2023
Members of the ACIP voted on Friday to recommend Pfizer’s maternal bivalent RSVpreF vaccine to protect newborns from severe RSV illness.
September 5th 2023
Results from a new study suggest that postnatal SSRI treatment may be beneficial in the long term for both women with postpartum depression and their children.
August 22nd 2023
The FDA approved Abrysvo for use in pregnant individuals to prevent LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.
August 7th 2023
The US FDA approved zuranolone 50 mg as the first oral, once-daily treatment for postpartum depression in adults.